Lidocaine/tetracaine topical cream - Crescita Therapeutics

Drug Profile

Lidocaine/tetracaine topical cream - Crescita Therapeutics

Alternative Names: Flexicaine; Pliaglis; S-Caine™ Peel; Tetracaine/lidocaine topical cream - Crescita Therapeutics

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZARS
  • Developer Crescita Therapeutics; Galderma; Nuvo Research
  • Class Acetanilides; Aminobenzoic acids; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Procedural pain
  • Phase II Unspecified
  • Discontinued Postherpetic neuralgia

Most Recent Events

  • 15 Aug 2017 Crescita Therapeutics has patent protection for Lidocaine/tetracaine topical cream in USA
  • 25 Apr 2017 Lidocaine/tetracaine topical cream licensed to Taro Pharmaceuticals Inc in USA
  • 09 Sep 2016 Lidocaine/tetracaine topical cream - Crescita Therapeutics is available for licensing in Mexico as of 09 Sep 2016. www.crescitatherapeutics.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top